Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MetAnEnd-HF
NCT05277415Phase 2Completed
- Start
- Feb 2013
- Primary completion
- May 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised trial in heart failure with reduced ejection fraction (HFrEF) comparing Ghrelin infusion with Placebo (2 arms). Primary endpoint: Change in cardiac output between treatment groups at 120 minutes. Started Feb 2013; status: completed.
02
Drugs
human ghrelin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT05277415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05277415.